<DOC>
	<DOCNO>NCT02203773</DOCNO>
	<brief_summary>This Phase 1b , open-label , non-randomized , multicenter study evaluate safety orally administer ABT-199 combined decitabine azacitidine preliminary efficacy combination . In addition , DDI sub-study single site , assess pharmacokinetics safety ABT-199 combination posaconazole .</brief_summary>
	<brief_title>Phase 1b Acute Myelogenous Leukemia ( AML ) Study With ABT-199 + Decitabine Azacitidine ( Chemo Combo )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>1 . Subject must confirmation AML WHO criteria25 ineligible treatment standard cytarabine anthracycline induction regimen due comorbidity factor . 2 . Subject must receive prior treatment AML exception hydroxyurea . 3 . Subject must ≥ 60 year age . 4 . Subject must project life expectancy least 12 week . 5 . Subject must consider ineligible induction therapy define follow : ≥ 75 year age ; OR ≥ 60 74 year least one follow comorbidities : ECOG Performance Status 2 3 ; Cardiac history CHF require treatment Ejection Fraction ≤ 50 % chronic stable angina ; DLCO ≤ 65 % FEV1 ≤ 65 % ; Creatinine clearance ≥ 30 mL/min &lt; 45 ml/min Moderate hepatic impairment total bilirubin &gt; 1.5 ≤ 3.0 × ULN Any comorbidity physician judge incompatible intensive chemotherapy must review approve study medical monitor study enrollment 6 . Subject must Eastern Cooperative Oncology Group ( ECOG ) Performance status : 0 2 subject ≥ 75 year age OR 0 3 subject ≥ 60 74 year age . 7 . Subject must adequate renal function demonstrate calculated creatinine clearance ≥ 30 mL/min ; determine via urine collection 24hour creatinine clearance Cockcroft Gault formula . 8 . Subject must adequate liver function demonstrate : aspartate aminotransferase ( AST ) ≤ 3.0 × ULN* alanine aminotransferase ( ALT ) ≤ 3.0 × ULN* bilirubin ≤ 1.5 × ULN* ○ Subjects &gt; 60 74 year age may bilirubin ≤ 3.0 × ULN* * unless consider due leukemic organ involvement . 9 . Nonsterile male subject must use contraceptive method partner ( ) prior begin study drug administration continue 90 day last dose study drug . Male subject must agree refrain sperm donation initial study drug administration 90 day last dose study drug . 10 . Female subject must either : Postmenopausal ; define Age &gt; 55 year menses 12 month without alternative medical cause ; OR Permanently surgical sterile ( bilateral oophorectomy , bilateral salpingectomy hysterectomy ) . 1 . Subject receive treatment follow : hypomethylating agent and/or chemo therapeutic agent Myelodysplastic syndrome [ MDS ] ) CART cell therapy Other experimental therapy AML . 2 . Subject history Myloproliferative Neoplasm ( MPN ) . 3 . Subject favorable risk cytogenetics categorize NCCN Guidelines Version 2 , 2016 Acute Myeloid Leukemia ( Appendix D ) . 4 . Subject ( 8 ; 21 ) , inv ( 16 ) , ( 16 ; 16 ) ( 15 ; 17 ) karyotype abnormality . 5 . Subject acute promyelocytic leukemia . 6 . Subject know active CNS involvement AML . 7 . Subject know positive HIV . Note : HIV test require . 8 . Subject know positive hepatitis B C infection exception undetectable viral load . Note : Hepatitis B C test require subject serologic evidence prior vaccination HBV ( i.e. , HBs Ag , antiHBs+ antiHBc ) may participate . 9 . Subject receive strong and/or moderate CYP3A inducer within 7 day prior initiation study treatment . 10 . Subject consume grapefruit , grapefruit product , Seville orange ( include marmalade contain Seville orange ) Star fruit within 3 day prior initiation study treatment . 11 . Subject history clinically significant condition ( ) opinion investigator would adversely affect his/her participate study include , limited : cardiovascular disability status New York Heart Association Class ≥ 2 . Class 2 define cardiac disease patient comfortable rest ordinary physical activity result fatigue , palpitation , dyspnea , anginal pain . renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic , cardiovascular disease , bleed disorder independent leukemia , chronic respiratory disease require continuous oxygen use . 12 . Subject malabsorption syndrome condition preclude enteral route administration . 13 . Subject exhibit evidence uncontrolled systemic infection require therapy ( viral , bacterial fungal ) . 14 . Subject history malignancy prior study entry , exception : Adequately treat situ carcinoma breast cervix uterus ; Basal cell carcinoma skin localize squamous cell carcinoma skin ; Previous malignancy confine surgically resect ( treated modality ) curative intent . 15 . Subject white blood cell count &gt; 25 × 109/L . Note : Hydroxyurea permit meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>Treatment Naive AML</keyword>
	<keyword>ABT-199</keyword>
	<keyword>GDC-0199</keyword>
	<keyword>Untreated AML</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelogenous Leukemia</keyword>
</DOC>